Lixisenatide in type 2 diabetes: latest evidence and clinical usefulness

Therapeutic Advances in Chronic Disease
Sarah L Anderson, Jennifer M Trujillo

Abstract

Type 2 diabetes (T2D) is a highly prevalent disorder that affects millions of people worldwide. The hallmark of T2D is hyperglycemia and, while many treatment modalities exist, achieving and maintaining glycemic control can be challenging. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are an appealing treatment option as they improve glycemic control, reduce weight, and limit the risk of hypoglycemia. Lixisenatide is a once-daily GLP-1 RA that has been evaluated in the GetGoal clinical trial program and has demonstrated efficacy and tolerability across a spectrum of patients. The feature that most distinguishes lixisenatide from other GLP-1 RAs is its ability to substantially reduce postprandial glucose (PPG) for the meal immediately following injection. Because of its positive effects on PPG, lixisenatide is being considered as a replacement for prandial insulin, and a fixed dose combination product containing lixisenatide and basal insulin is in development. Lixisenatide is a promising new addition to the antidiabetic armamentarium, but due to the lack of real-world experience with the drug, its exact place in therapy is unknown.

References

Mar 21, 2008·Trends in Molecular Medicine·Jens J HolstSten Madsbad
Apr 8, 2010·The Annals of Pharmacotherapy·Sarah L Anderson, Jennifer M Trujillo
Jul 5, 2013·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Andreas B Petersen, Mikkel Christensen
Oct 15, 2013·Diabetic Medicine : a Journal of the British Diabetic Association·G B BolliM Hanefeld
Aug 20, 2012·Journal of Diabetes Investigation·Daisuke Yabe, Yutaka Seino
May 31, 2014·Journal of Diabetes Science and Technology·Udo StauderSteve Edelman
Dec 30, 2014·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Aug 27, 2016·Expert Opinion on Investigational Drugs·Brian TomlinsonZhong-Min Liu
Nov 4, 2016·Expert Opinion on Drug Metabolism & Toxicology·Markolf HanefeldLouis Monnier
Aug 25, 2017·Current Medical Research and Opinion·Ronald M Goldenberg, Lori Berard
Jul 31, 2019·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Sanjay KalraManilka Sumanatilleke
Jun 28, 2018·Hormones : International Journal of Endocrinology and Metabolism·Dimitrios SfairopoulosEvangelos Liberopoulos
May 8, 2018·Nature Reviews. Endocrinology·Andreas AndersenTina Vilsbøll
Jun 22, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Markolf HanefeldJochen Seufert
Feb 5, 2021·International Journal of Pharmaceutics·Noura G EissaAyat Allam
Feb 6, 2020·Bioorganic & Medicinal Chemistry·Jayanta Dowarah, Ved Prakash Singh
Jul 4, 2020·Biochemical Pharmacology·Helen C MendelMarkus Muttenthaler

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

Mono
GetGoal
Asia
LixiLan

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.